Welcome to our dedicated page for Johnson & Johnson news (Ticker: JNJ), a resource for investors and traders seeking the latest updates and insights on Johnson & Johnson stock.
Johnson & Johnson reports healthcare developments across its Innovative Medicine and MedTech businesses. News commonly covers clinical and scientific data in immunology, oncology, neurology and neuropsychiatry, including medicines and candidates such as CAPLYTA, TREMFYA, JNJ-4804, seltorexant and the INVEGA long-acting injectable schizophrenia portfolio.
Company updates also include medical technology programs such as the investigational OTTAVA robotic surgical system, product and patient-education initiatives, quarterly sales and earnings releases, dividend actions, investor presentations and governance or investor-relations appointments.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Johnson & Johnson (NYSE: JNJ) will participate in the Bernstein 39th Annual Strategic Decisions Conference on May 31st at the New York Hilton Midtown. Joaquin Duato, Chairman of the Board and CEO, will represent the company in a session scheduled for 10:00 a.m. (Eastern Time).
This event will be accessible to investors and interested parties via the Johnson & Johnson website at www.investor.jnj.com. A replay of the webcast will be available approximately 48 hours after the live session.
Johnson & Johnson (NYSE: JNJ) has announced the launch of a roadshow for the initial public offering (IPO) of its subsidiary, Kenvue Inc., offering 151,204,000 shares at an expected price of $20.00 to $23.00 per share. The underwriters will have a 30-day option to purchase an extra 22,680,600 shares. After the IPO, JNJ will hold 91.9% of Kenvue's shares. Goldman Sachs, J.P. Morgan, and BofA Securities are leading the IPO, with a registration statement filed with the SEC that is not yet effective. The press release emphasizes the commitment of JNJ to health and wellness, along with a cautionary note on forward-looking statements regarding the IPO and economic factors impacting Kenvue's success as a standalone company.
Lawyers for around 55,000 plaintiffs in the lawsuit against Johnson & Johnson (JNJ) over cancer-linked talcum powder have formed an Ad Hoc Committee. They support an $8.9 billion settlement aimed at resolving a lengthy legal battle. LTL Management, a J&J subsidiary, is again filing for Chapter 11 bankruptcy to create a trust for compensating affected victims.
The proposed settlement includes removing all talc-based products globally and ensuring compensation for current claimants within a year. The Ad Hoc Committee, which has retained bankruptcy counsel, needs a 75% claimant approval for the settlement to pass. This follows scientific evidence linking J&J's products to serious health issues, as well as previous bankruptcy attempts that were rejected by the courts.